GMAB
$32.31
Genmab A\/S ADR
$1.22
3.92%
GMAB
Earnings Whisper ®
N/A
2nd Quarter June 2022
Consensus:  $0.21
Revenue:  $436.41 Mil
Wednesday
Aug 10
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when GMAB reports earnings?
Beat
Meet
Miss

Where is GMAB's stock price going from here?
Up
Flat
Down
Stock chart of GMAB
Analysts
Summary of analysts' recommendations for GMAB
Score
Grade
Pivots
Resistance
$33.48
$32.91
$32.61

$32.04

Support
$31.74
$31.17
$30.87
Tweet
Growth
Description
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.